Halozyme Therapeutics Inc. took a double hit Thursday as FDA concerns about its recombinant human hyaluronidase (rHuPH20) enzyme sidetracked programs at two partners and sent the stock into a tailspin. Read More
Incyte Corp.'s launch of Jakafi (ruxolitinib) for myelofibrosis continues to gather momentum as physicians gradually expand its use to less severely ill patients. The Wilmington, Del.-based company reported Jakafi sales of $31.9 million for the second quarter of 2012, and $53.1 million for the first six months of the year. Read More
Pharming Group NV is planning to downsize operations at its headquarters in Leiden, the Netherlands, and has put in place additional working capital facilities as its day of reckoning approaches. Read More
• Oragenics Inc., of Tampa, Fla., completed a $13 million private placement, selling an aggregate of 8.7 million shares of common stock to accredited investors at $1.50 per share. Read More
• Genta Inc., of Berkeley Heights, N.J., said in an SEC filing Thursday that it intends to file a voluntary petition for relief under Chapter 7 of the Bankruptcy Code in the Bankruptcy Court for the District of Delaware. Upon the filing, a Chapter 7 trustee will assume control of the company and the assets will be liquidated in accordance with the Chapter 7 code. Read More
• DBV Technologies, of Bagneux, France, said the first patient has been enrolled in the VIPES Phase IIb study of Viaskin, an epicutaneous immunotherapy approach to desensitizing against peanut allergy via a skin patch. A total of 220 peanut-allergic subjects, ranging in age from 6 to 55, with a history of immediate hypersensitive reaction to peanut protein, will be enrolled in the study. Read More
